The present invention is directed to certain novel compounds represented by structural Formula (I) ##STR1## or pharmaceutically acceptable salt forms thereof, wherein R.sup.1, R.sup.5, R.sup.6a, R.sup.6b, R.sup.7, R.sup.8, R.sup.9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

A invenção atual é dirigida a determinados compostos da novela representados pelo ## estrutural do ## STR1 da fórmula (I) ou pharmaceutically o sal aceitável dá forma disso, wherein R.sup.1, R.sup.5, R.sup.6a, R.sup.6b, R.sup.7, R.sup.8, R.sup.9, X, b, k, m, e n, e as linhas tracejadas são descritos nisto. A invenção é concernida também com os formulations pharmaceutical que compreendem estes compostos da novela como ingredientes ativos e o uso dos compostos da novela e de seus formulations no tratamento de determinados disorders. Os compostos desta invenção são agonists e antagonistas do serotonin e são úteis no controle ou na prevenção de disorders do sistema nervoso central including o obesity, a ansiedade, o depression, o psychosis, a esquizofrenia, os disorders do sono, disorders sexual, migraine, circunstâncias associadas com a dor cephalic, phobias sociais, e disorders gastrointestinal tais como o dysfunction do motility do intervalo gastrointestinal.